Aeterna Zentaris Announces Election of Directors at 2017 Shareholders' Meeting
May 09 2017 - 4:30PM
Business Wire
Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the “Company”),
a specialty biopharmaceutical company engaged in developing and
commercializing novel treatments in oncology, endocrinology and
women’s health, today announced the results of the vote on
directors held at its 2017 annual meeting of shareholders held
earlier today on May 9, 2017. Each of the director nominees
proposed by management for election was elected as director,
without a vote by ballot being conducted. The Company received
proxies with regard to voting on the six directors nominated for
election as set forth in the table below:
Name of Nominee
Votes For %
Votes Withheld % Michael Cardiff
706,745 75.06
234,809 24.94 David A. Dodd
754,297 80.11
187,257 19.89 Carolyn Egbert
729,161 77.44
212,393 22.56 Juergen Ernst
731,223 77.66
210,331 22.34 Gérard Limoges
707,611 75.15
233,943 24.85 Ken Newport
740,594 78.66
200,960 21.34
All other matters at the shareholders' meeting were also
approved by shareholders.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel pharmaceutical
therapies. We are engaged in drug development activities and in the
promotion of products for others. We recently completed Phase 3
studies of two internally developed compounds. The focus of our
business development efforts is the acquisition of licenses to
products that are relevant to our therapeutic areas of focus. We
also intend to license out certain commercial rights of internally
developed products to licensees in non-U.S. territories where such
out-licensing would enable us to ensure development, registration
and launch of our product candidates. Our goal is to become a
growth-oriented specialty biopharmaceutical company by pursuing
successful development and commercialization of our product
portfolio, achieving successful commercial presence and growth,
while consistently delivering value to our shareholders, employees
and the medical providers and patients who will benefit from our
products. For more information, visit www.aezsinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170509006204/en/
Aeterna Zentaris Inc.Philip A. Theodore, 843-900-3223Senior Vice
Presidentir@aezsinc.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024